Australian M&A and equity raisings
2,041 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
9 deals · A$169mdisclosed · Medtech · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value A$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Aug 2024 | Evolution Surgical | – | Quadrant Private Equity | Stake | Announced | – | Medtech | Herbert Smith Freehills Kramer (buy-side)Boston Consulting Group (buy-side)KPMG (buy-side)GreenMount (buy-side) |
| Jun 2025 | Lyrebird Health | – | – | Stake | Completed | – | Medtech | Herbert Smith Freehills Kramer (sell-side)Corrs Chambers Westgarth (sell-side) |
| Jul 2025 | Bluechiip Limited (ASX:BCT) and its US-based subsidiary, the Bluechiip Group | – | Cryonix | Asset sale | Announced | – | Medtech | Moray & Agnew (sell-side)Mills Oakley (buy-side) |
| Feb 2026 | Southern Cross Diagnostics | – | Novacyt SA | Acquisition | Completed | – | Medtech | Hamilton Locke (buy-side)Addleshaw Goddard (buy-side)Frieh, Brault & Associés (buy-side) |
| Feb 2026 | SAVI Surgical | – | Smartways Logistics | Acquisition | Completed | – | Medtech | Record Point (sell-side) |
| Feb 2026 | SDI | Jeffery James Cheetham | Beijing Guoci Kebo Technology Co. | Scheme | Completed | 166.4 | Medtech | Houlihan Lokey (sell-side)DLA Piper (sell-side)Rothschild & Co (buy-side)Herbert Smith Freehills Kramer (buy-side) |
| May 2026 | Kyra flow products | Telstra Health | Alcidion Group | Asset sale | Announced | 3.0 | Medtech | Henslow (buy-side)Arnold Bloch Leibler (buy-side) |
| Sep 2026 | Microba Life Sciences | – | Genetic Signatures | Scheme | Announced | – | Medtech | Latimer Partners (sell-side)Thomsons (sell-side)AE Advisors (buy-side)Gadens (buy-side) |
| Oct 2026 | Heidi | – | Blackbird | Stake | Completed | – | Medtech | Ashurst Perkins Coie (sell-side) |
Deals come from ASX announcements, scheme booklets, prospectuses, the advisers' own deal announcements and the press. How the data is built